Condition: Endometrial Cancer · Sponsor: Karyopharm Therapeutics Inc
This is a prospective, multicenter, double-blind, placebo-controlled, randomized Phase 3 study. The purpose of the study is to obtain evidence of efficacy for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recurrent disease who are in partial or complete response after having completed a single line of at least 12 weeks of taxane-platinum combo therapy will be randomized in a 2:1 manner to maintenance therapy with 80 milligram (mg) with selinexor once weekly (QW) or placebo until progression.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Arizona Oncology | Tucson, Arizona, United States | — |
| Stanford University | Palo Alto, California, United States | — |
| Moffitt Cancer Center | Tampa, Florida, United States | — |
| Florida Cancer Specialists (Sarah Cannon Research Institute) | West Palm Beach, Florida, United States | — |
| Gynecological Cancer Institute of Chicago | Oak Lawn, Illinois, United States | — |
| Parkview Research Center | Fort Wayne, Indiana, United States | — |
| Indiana University Simon Cancer Center | Indianapolis, Indiana, United States | — |
| HCA Midwest Health - Kansas City (Sarah Cannon Research Institute) | Kansas City, Missouri, United States | — |
| NYU Langone | New York, New York, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| University of Oklahoma Health Sciences Center - Stephenson Cancer Center | Oklahoma City, Oklahoma, United States | — |
| Oncology Associates of Oregon | Eugene, Oregon, United States | — |
+ 66 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03555422